{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:21:12Z","timestamp":1776835272021,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Corrona, LLC"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40744-018-0129-z","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T05:32:37Z","timestamp":1540272757000},"page":"537-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry"],"prefix":"10.1007","volume":"5","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Karki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"129_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4329\/wjr.v7.i9.236","volume":"7","author":"M Ghasemi-Rad","year":"2015","unstructured":"Ghasemi-Rad M, Attaya H, Lesha E, et al. Ankylosing spondylitis: a state of the art factual backbone. World J Radiol. 2015;7:236\u201352.","journal-title":"World J Radiol."},{"key":"129_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","volume":"341","author":"JD Reveille","year":"2011","unstructured":"Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011;341:284\u20136.","journal-title":"Am J Med Sci"},{"key":"129_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","volume":"345","author":"JD Reveille","year":"2013","unstructured":"Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345:431\u20136.","journal-title":"Am J Med Sci"},{"key":"129_CR4","first-page":"249","volume":"51","author":"SA Shaikh","year":"2007","unstructured":"Shaikh SA. Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc. 2007;51:249\u201360.","journal-title":"J Can Chiropr Assoc."},{"key":"129_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"129_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr.20408","volume":"63","author":"A Bremander","year":"2011","unstructured":"Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2011;63:550\u20136.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"129_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/ard.2009.116178","volume":"69","author":"JH Kang","year":"2010","unstructured":"Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis. 2010;69:1165\u20138.","journal-title":"Ann Rheum Dis"},{"key":"129_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11926-014-0434-7","volume":"16","author":"C Mercieca","year":"2014","unstructured":"Mercieca C, van der Horst-Bruinsma IE, Borg AA. Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice. Curr Rheumatol Rep. 2014;16:434.","journal-title":"Curr Rheumatol Rep"},{"key":"129_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13075-014-0418-z","volume":"16","author":"JJ Meesters","year":"2014","unstructured":"Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M. The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther. 2014;16:418.","journal-title":"Arthritis Res Ther."},{"key":"129_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/03009742.2013.863969","volume":"43","author":"LM Sun","year":"2014","unstructured":"Sun LM, Muo CH, Liang JA, Chang SN, Sung FC, Kao CH. Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Scand J Rheumatol. 2014;43:301\u20136.","journal-title":"Scand J Rheumatol"},{"key":"129_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis"},{"key":"129_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol."},{"key":"129_CR13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:1926\u20138.","journal-title":"Ann Rheum Dis"},{"key":"129_CR14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667\u201375.","journal-title":"Arthritis Rheum"},{"key":"129_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187\u201393.","journal-title":"Lancet"},{"key":"129_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594\u2013600.","journal-title":"Ann Rheum Dis"},{"key":"129_CR17","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum"},{"key":"129_CR18","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:2091\u2013102.","journal-title":"Arthritis Rheumatol."},{"key":"129_CR19","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"129_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"129_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"129_CR22","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67:2702\u201312.","journal-title":"Arthritis Rheumatol."},{"key":"129_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.38973","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, Landewe R, Rudwaleit M, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol. 2015;67:668\u201377.","journal-title":"Arthritis Rheumatol."},{"key":"129_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum"},{"key":"129_CR25","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"129_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","volume":"47","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NW, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897\u2013900.","journal-title":"Rheumatology (Oxford)"},{"key":"129_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2004.029900","volume":"64","author":"SN Nikas","year":"2005","unstructured":"Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis. 2005;64:940\u20132.","journal-title":"Ann Rheum Dis"},{"key":"129_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/1756-185x.12018","volume":"17","author":"DS Prince","year":"2014","unstructured":"Prince DS, McGuigan LE, McGirr EE. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis. 2014;17:165\u201372.","journal-title":"Int J Rheum Dis."},{"issue":"e009661","key":"129_CR29","first-page":"2015","volume":"6","author":"P Rahman","year":"2016","unstructured":"Rahman P, Choquette D, Bensen WG, et al. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open. 2016;6(e009661):2015\u2013009661.","journal-title":"BMJ Open"},{"key":"129_CR30","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","volume":"52","author":"A Spadaro","year":"2013","unstructured":"Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. Rheumatology (Oxford). 2013;52:1914\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"129_CR31","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.","journal-title":"Arthritis Res Ther."},{"key":"129_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664\u201374.","journal-title":"Adv Ther."},{"key":"129_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/ard.2004.028753","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64:659\u201363.","journal-title":"Ann Rheum Dis"},{"key":"129_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12325-014-0110-3","volume":"31","author":"J Yeaw","year":"2014","unstructured":"Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31:410\u201325.","journal-title":"Adv Ther."},{"key":"129_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","volume":"18","author":"A Ciurea","year":"2016","unstructured":"Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18:71.","journal-title":"Arthritis Res Ther."},{"key":"129_CR36","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.","journal-title":"Arthritis Res Ther."},{"key":"129_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157\u201363.","journal-title":"Ann Rheum Dis"},{"key":"129_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"129_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47:343\u201350.","journal-title":"Semin Arthritis Rheum"},{"key":"129_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234\u201340.","journal-title":"Arthritis Rheum"},{"key":"129_CR41","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","volume":"42","author":"AV Heinonen","year":"2015","unstructured":"Heinonen AV, Aaltonen KJ, Joensuu JT, et al. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol. 2015;42:2339\u201346.","journal-title":"J Rheumatol"},{"key":"129_CR42","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8\u00a0years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002\u20138.","journal-title":"Ann Rheum Dis"},{"key":"129_CR43","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken). 2010;62:1362\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"129_CR44","first-page":"1010","volume":"29","author":"S Dadoun","year":"2011","unstructured":"Dadoun S, Geri G, Paternotte S, Dougados M, Gossec L. Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients. Clin Exp Rheumatol. 2011;29:1010\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"129_CR45","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/rheumatology\/kev001","volume":"54","author":"JL Rosales-Alexander","year":"2015","unstructured":"Rosales-Alexander JL, Balsalobre Aznar J, Perez-Vicente S, Magro-Checa C. Drug survival of anti-tumour necrosis factor alpha therapy in spondyloarthropathies: results from the Spanish emAR II study. Rheumatology (Oxford). 2015;54:1459\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"129_CR46","doi-asserted-by":"publisher","first-page":"e0131864","DOI":"10.1371\/journal.pone.0131864","volume":"10","author":"JW Lee","year":"2015","unstructured":"Lee JW, Kang JH, Yim YR, et al. Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. PLoS ONE. 2015;10:e0131864.","journal-title":"PLoS ONE"},{"key":"129_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72:1149\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"129_CR48","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","volume":"15","author":"K Gulyas","year":"2014","unstructured":"Gulyas K, Bodnar N, Nagy Z, et al. Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis. Eur J Health Econ. 2014;15(Suppl 1):S93\u2013100.","journal-title":"Eur J Health Econ."},{"key":"129_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3904\/kjim.2016.042","volume":"33","author":"H Jeong","year":"2018","unstructured":"Jeong H, Eun YH, Kim IY, et al. Drug survival of tumor necrosis factor alpha inhibitors in patients with ankylosing spondylitis in Korea. Korean J Intern Med. 2018;33:407\u201316.","journal-title":"Korean J Intern Med"},{"key":"129_CR50","first-page":"1236","volume":"20","author":"A Howe","year":"2014","unstructured":"Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20:1236\u201344.","journal-title":"J Manag Care Spec Pharm."},{"key":"129_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664\u201374.","journal-title":"Adv Ther."},{"key":"129_CR52","first-page":"S6","volume-title":"Treatment patterns and costs for ant-TNF alpha therapy in patients with ankylosing spondylitis","author":"JB Palmer","year":"2015","unstructured":"Palmer JB, Li Y, Herrera V, Liao M, Ozturk Z. Treatment patterns and costs for ant-TNF alpha therapy in patients with ankylosing spondylitis. Rheum: Curr Res; 2015. p. S6."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-018-0129-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:37:42Z","timestamp":1724456262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-018-0129-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s40744-018-0129-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"17 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}